Disrupting the endothelin and Wnt relationship to overcome chemoresistance

Abstract

Knowledge of the mechanisms underlying chemoresistance is important in the development of novel targeted treatments for ovarian cancer. We recently reported that targeting endothelin A receptor/β-arrestin-1, a binding partner of Wnt/β-catenin, is sufficient to sensitize ovarian cancer to chemotherapy. This result highlights endothelin-1 receptor antagonists as potential anticancer therapeutics.